Unlike the Oncology Care Model, the Enhancing Oncology Model will focus on 7 common cancer types, which experts say offers advantages and disadvantages for practices.
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, led a discussion on a pros and cons of limiting the Enhancing Oncology Model (EOM) to 7 common cancer types. Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agreed that honing in common cancers could lead to better predictability in cost of care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, raised concerns that lack of monthly payments for other cancer types for harm practices giving patients supportive services; Divers and Schleicher concurred on the potential effects on quality.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen